Moleculin Biotech, Inc. (MBRX)
0.4856
0.00 (0.00%)
USD |
NASDAQ |
Oct 05, 16:00
0.4856
0.00 (0.00%)
After-Hours: 20:00
Moleculin Biotech Enterprise Value : -3.514M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | -3.514M |
| October 01, 2026 | -3.393M |
| September 30, 2026 | -3.417M |
| September 29, 2026 | -3.233M |
| September 28, 2026 | -2.930M |
| September 25, 2026 | -2.699M |
| September 24, 2026 | -2.945M |
| September 23, 2026 | -3.222M |
| September 22, 2026 | -2.958M |
| September 21, 2026 | -3.277M |
| September 18, 2026 | -1.481M |
| September 17, 2026 | -1.432M |
| September 16, 2026 | -1.716M |
| September 15, 2026 | -1.634M |
| September 14, 2026 | -1.466M |
| September 11, 2026 | -1.894M |
| September 10, 2026 | -1.078M |
| September 09, 2026 | -1.538M |
| September 08, 2026 | -1.644M |
| September 04, 2026 | -1.930M |
| September 03, 2026 | -2.174M |
| September 02, 2026 | -2.043M |
| September 01, 2026 | -2.355M |
| August 31, 2026 | -2.393M |
| August 28, 2026 | -2.356M |
| Date | Value |
|---|---|
| August 27, 2026 | -2.080M |
| August 26, 2026 | -2.71M |
| August 25, 2026 | -2.632M |
| August 24, 2026 | -2.644M |
| August 21, 2026 | -2.760M |
| August 20, 2026 | -2.777M |
| August 19, 2026 | -2.909M |
| August 18, 2026 | -2.638M |
| August 17, 2026 | -2.660M |
| August 14, 2026 | -2.623M |
| August 13, 2026 | -2.914M |
| August 12, 2026 | -3.262M |
| August 11, 2026 | -3.810M |
| August 10, 2026 | -3.914M |
| August 07, 2026 | -4.063M |
| August 06, 2026 | -4.236M |
| August 05, 2026 | -4.201M |
| August 04, 2026 | -4.063M |
| August 03, 2026 | -3.952M |
| July 31, 2026 | -4.13M |
| July 30, 2026 | 0.272M |
| July 29, 2026 | 2.686M |
| July 28, 2026 | 8.579M |
| July 27, 2026 | 8.579M |
| July 24, 2026 | 8.082M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
| Biogen, Inc. | 39.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.635M |
| Total Expenses (Quarterly) | 7.635M |
| EPS Diluted (Quarterly) | -1.402 |
| Earnings Yield | -3.53K% |
| Normalized Earnings Yield | -3058.86 |